Advertisement

Topics

Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

02:00 EDT 17 Aug 2017 | InvestorIdeas

August 17, 2017 (Investorideas.com Newswire) Analyst Ram Selvaraju with H.C. Wainwright & Co. provided an update on this biotech company's REVEAL clinical programs, as well as Q2/17 earnings that exceeded expectations.

Original Article: Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection

NEXT ARTICLE

More From BioPortfolio on "Immunotherapy Company's Q2 Revenue 'Handily Beats' H.C. Wainwright's Projection"

Advertisement
Quick Search
Advertisement
Advertisement